SPS3 was an international trial examining effective
therapies for secondary prevention in lacunar stroke patients.
Elderly were defined as those > 75 years at study entry and
compared to patients < 75 years on adherence to therapies,
presence of side effects, and risk of recurrent stroke, major vascular
events, and deaths